Outfitter Financial LLC Raises Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Outfitter Financial LLC increased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 0.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 33,317 shares of the medical equipment provider’s stock after acquiring an additional 205 shares during the period. Boston Scientific comprises 1.7% of Outfitter Financial LLC’s portfolio, making the stock its 21st biggest position. Outfitter Financial LLC’s holdings in Boston Scientific were worth $1,926,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Bruce G. Allen Investments LLC purchased a new position in Boston Scientific during the 4th quarter worth $28,000. Venturi Wealth Management LLC increased its stake in shares of Boston Scientific by 58.0% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 215 shares during the period. Motco raised its holdings in shares of Boston Scientific by 136.3% in the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 372 shares in the last quarter. Cetera Trust Company N.A bought a new stake in shares of Boston Scientific in the fourth quarter valued at about $43,000. Finally, Asset Dedication LLC lifted its stake in Boston Scientific by 42.6% in the third quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 235 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE BSX traded down $0.29 during midday trading on Friday, reaching $73.81. The company had a trading volume of 1,319,716 shares, compared to its average volume of 6,531,991. The stock has a market cap of $108.29 billion, a P/E ratio of 62.08, a P/E/G ratio of 2.51 and a beta of 0.77. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $74.39. The business’s 50-day simple moving average is $68.95 and its 200 day simple moving average is $61.90.

Wall Street Analyst Weigh In

Several research firms have recently commented on BSX. Oppenheimer boosted their price target on shares of Boston Scientific from $58.00 to $68.00 and gave the company a “market perform” rating in a report on Thursday, February 1st. UBS Group boosted their price objective on shares of Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Citigroup upped their target price on Boston Scientific from $79.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Needham & Company LLC lifted their price target on Boston Scientific from $71.00 to $82.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, Evercore ISI upped their price objective on Boston Scientific from $72.00 to $78.00 and gave the stock an “outperform” rating in a research note on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $75.09.

Insider Buying and Selling

In related news, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Boston Scientific news, Director Charles J. Dockendorff sold 3,946 shares of the stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total transaction of $286,874.20. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares of the company’s stock, valued at approximately $2,690,551.22. The disclosure for this sale can be found here. Insiders sold 82,330 shares of company stock worth $5,682,434 in the last 90 days. Insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.